Latest Chlamydiae Stories

Michael Harper for redOrbit.com – Your Universe Online Blame it on their small stature. Blame it on their soft fur. For what could be a myriad of reasons, Koalas would almost certainly win the “Most Cuddly” award amongst all of the familiar marsupials. Sadly, like all other creatures – cute and ugly alike – Koalas also have a tendency to get sick from time to time. According Dr. Adam Polkinghorne and a host of researchers with Queensland University of Technology (QUT), these...

SUNNYVALE, Calif., Jan. 15, 2013 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the U.S. Food & Drug Administration (FDA) has categorized Cepheid's Xpert(®) CT/NG test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA). Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The test runs on Cepheid's GeneXpert(®) Systems and is...

SUNNYVALE, Calif., Dec. 27, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert(®) CT/NG. Running on Cepheid's GeneXpert(®) Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the first time, same-day patient consultation and treatment is possible for...

HAMILTON, N.J., Sept. 11, 2012 /PRNewswire/ -- Medical Diagnostic Laboratories, L.L.C. (MDL), a CLIA-certified infectious disease laboratory which specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses, announced that it is now offering an azithromycin resistance reflex assay for Chlamydia trachomatis. MDL is believed to be the first and only clinical laboratory to offer the antibiotic resistance for this sexually transmitted pathogen. Drug...

A recent study posted in Nature Genetics explains that researchers have found that Chlamydia has been evolving differently than previously thought. The researchers used whole genome sequencing to find these results. Their findings show the exchange of DNA between different strains of the STD to form new strains is more common than expected. The researchers came about their findings while working with hospitals to improve their testing and detection of Chlamydia, particularly different...

Whole genome analysis of Chlamydia trachomatis highlights risks with current method of tracking In a study released today in Nature Genetics, researchers have found that Chlamydia has evolved more actively than was previously thought. Using whole genome sequencing the researchers show that the exchange of DNA between different strains of Chlamydia to form new strains is much more common than expected. The team highlights that current clinical testing methods do not capture the variation...

According to a report by the U.S. Centers for Disease Control and Prevention (CDC), half of Americans with chlamydia do not know they have it, and it is the top sexually transmitted disease (STD) reported to public health authorities. The U.S. Centers for Disease Control and Prevention's annual report on sexually transmitted diseases, which tracks cases of chlamydia, gonorrhea, and syphilis, has shown widespread disparities. The report said that the number two reported STD is gonorrhea,...

A breakthrough in the study of chlamydia genetics could open the way to new treatments and the development of a vaccine for this sexually transmitted disease. For decades research progress has been hampered because scientists have been prevented from fully understanding these bacteria as they have been unable to manipulate the genome of Chlamydia trachomatis. Now researchers in Southampton have made a significant breakthrough in accessing the chlamydial genome and believe it could pave...

(Ivanhoe Newswire) – A weakened strain of Chlamydia trachomatis bacteria may be used as a vaccine to prevent or reduce the severity of trachoma, the world’s leading cause of infectious blindness, according to this study conducted on monkeys. "This work is an important milestone in the development of a trachoma vaccine," Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) at NIH, was quoted as saying. "If this approach demonstrates...

NIH - developed vaccine based on live, attenuated Chlamydia bacteria An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys. "This work is an important milestone in the development of a trachoma vaccine," noted Anthony S. Fauci, M.D., director of the National Institute of Allergy...